Mortality among urban drug users and the impact of highly active antiretroviral therapy.

[1]  D. Bangsberg,et al.  Antiretroviral Therapy, Hepatitis C Virus, and AIDS Mortality Among San Francisco's Homeless and Marginally Housed , 2005, Journal of acquired immune deficiency syndromes.

[2]  R. Chaisson,et al.  Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy , 2001, AIDS.

[3]  A Muñoz,et al.  Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.

[4]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[5]  D. Vlahov,et al.  Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. , 2004, The Journal of infectious diseases.

[6]  Y. Lo,et al.  Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  L. Kalish,et al.  Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease , 2001, Annals of Internal Medicine.

[8]  Anne M Johnson,et al.  A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. , 1999, Journal of acquired immune deficiency syndromes.

[9]  S. Galea,et al.  Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. , 2005, American journal of epidemiology.

[10]  V. M. Shadle,et al.  Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.

[11]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[12]  B. Yip,et al.  Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.

[13]  P. Selwyn,et al.  Risk factors for human immunodeficiency virus infection in intravenous drug users. , 1989, The New England journal of medicine.

[14]  Mardge H. Cohen,et al.  Marked declines in human immunodeficiency virus-related mortality in Chicago in women, African Americans, Hispanics, young adults, and injection drug users, from 1995 through 1997. , 2000, Archives of internal medicine.

[15]  S. Holmberg,et al.  Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993–1999 , 2003, Journal of Urban Health.